Grant of Options

Stem Cell Sciences plc
29 April 2008


Press Release

For Immediate Release                                         29th April 2008
                             Stem Cell Sciences plc

                                Grant of Options

Stem Cell Sciences plc, the global biotechnology company focused on the
commercialisation of stem cells and stem cell technologies in research and
cell-based therapies, announces that on 25th April 2008, Dr Alastair J Riddell,
Chief Executive Officer, was granted options to acquire 162,500 new Ordinary
Shares in the Company at a price of 15 pence per share.

The options vest immediately following the execution of the successful
restructure of the Company and the strike price is based upon the average
trading price over the three days prior to the grant date of 25th April 2008.
                                   
                                     - Ends-

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)
Giorgio Reggiani, Company Secretary [phone]

Notes to Editors
Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) is a leading provider of cells
and cell culture media to the burgeoning stem cell research market. The
successful application of stem cells in both research and clinical applications
is reliant on the reproducible supply of pure, fully characterised stem cells
and stem cell-derived specialised cells such as nerves and muscle. By providing
these products, to the life sciences industry and academia for use in basic
research and drug discovery, Stem Cell Sciences has multiple potential revenue
streams.

Stem Cell Sciences has multiple industry collaborations, including Millipore
Corporation for the marketing and distribution of HEScGROTM, its serum free
media for the growth of human embryonic stem cells and Merck & Co for the use of
mouse neural stem cell technology for research applications. It recently
announced deals with a major pharmaceutical company in the field of diabetes
research and with the Myelin Repair Foundation in the USA in neurological
research.

To access cutting edge technologies on a rapid and on-going basis, Stem Cell
Sciences has built an exceptional network of highly interactive collaborations
with academic centres of excellence in the stem cell field. These collaborations
have been the source of our founding technologies and continue to provide an
expanding pipeline of products and intellectual property that are central to the
Company's strategy and success. For further information on the company please
visit: www.stemcellsciences.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange